- Home
- BDRX vs CVKD Comparison
BDRX vs CVKD Comparison
Compare BDRX & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BDRX | CVKD |
|---|---|---|
| Founded | 2000 | 2022 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0M | 20.7M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | BDRX | CVKD |
|---|---|---|
| Price | $2.86 | $7.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $32.00 |
| AVG Volume (30 Days) | ★ 2.6M | 82.1K |
| Earning Date | 09-12-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.10 | $6.75 |
| 52 Week High | $92.00 | $22.90 |
Technical Indicators
Market Signals| Indicator | BDRX | CVKD |
|---|---|---|
| Relative Strength Index (RSI) | 39.96 | 36.15 |
| Support Level | $4.55 | $6.75 |
| Resistance Level | $7.22 | $7.75 |
| Average True Range (ATR) | 1.48 | 1.00 |
| MACD | -0.26 | -0.22 |
| Stochastic Oscillator | 1.62 | 10.78 |
Price Performance
Historical ComparisonAbout BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.